>_ QFI Terminal
TerminalStocks › RVTY

Revvity, Inc. (RVTY) Stock

Healthcare · Medical - Diagnostics & Research · US
$100.00 +2.23%
Last updated Jun 18, 2026 23:54 UTC

RVTY Key Statistics

Market Cap$11.16B
P/E (TTM)47.62
P/S (TTM)3.84
P/B (TTM)1.56
Revenue (TTM)$2.90B
EPS (TTM)$2.10
Dividend Yield
ROE (TTM)3.28%
Net Margin8.30%
Gross Margin51.44%
52W High$118.30
52W Low$81.22
Analyst ViewBuy
Price Target$109.43
Employees11,000
Volume2,170,304

About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

CEO: Prahlad R. Singh. Company website

See RVTY live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open RVTY in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.